San Diego—In chronic lymphocytic leukemia (CLL), the activity of immunotherapies may be enhanced when they are administered in combination with ibrutinib not just after ibrutinib has failed, according to data from several preliminary studies. The possibility that these ibrutinib may have synergistic effects with some immunotherapy approaches is derived from evidence that ibrutinib influences T-cell function and the microenvironment.
Consistent with previously published evidence that prior